0.37

0.01% +0.000050

After Hours: .3701 0.000100 +0.03%

Kazia Therapeutics Limited ADR (KZIA)

Overview News Price History Option Chain Discussions Forecast Stock Split

Kazia Therapeutics Limited ADR stock is currently priced at $0.37, with a 24-hour trading volume of 55,547. It has seen a +0.01% increased in the last 24 hours and a +17.24% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $0.3706 pivot point. If it approaches the $0.3393 support level, significant changes may occur.

Previous Close:

$0.37

Open:

$0.37284

24h Volume:

55,547

Market Cap:

$9.75M

Revenue:

Net Income/Loss:

$-13.52M

P/E Ratio:

-0.50

EPS:

-0.74

Net Cash Flow:

$-10.03M

1W Performance:

-1.60%

1M Performance:

+17.24%

6M Performance:

-35.09%

1Y Performance:

-72.59%

1D Range:

$0.357

$0.389

52W Range:

$0.1866

$1.41

Kazia Therapeutics Limited ADR Stock (KZIA) Company Profile

Name

Kazia Therapeutics Limited ADR

Sector

Healthcare (1199)

Industry

Biotechnology (688)

Phone

Address

Three International Towers, Level 24 300 Barangaroo Avenue, Sydney, NSW

Employee

Twitter

@KaziaTx

Next Earnings Date

2024-03-25

Latest SEC Filings

KZIA's Discussions on Twitter

Kazia Therapeutics Limited ADR Stock (KZIA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-14-21	Initiated	Maxim Group	Buy
Jan-05-21	Initiated	H.C. Wainwright	Buy

Kazia Therapeutics Limited ADR Stock (KZIA) Latest News

Why NextPlat Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket

Benzinga

Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Benzinga

Kazia Therapeutics Limited ADR Stock (KZIA) Financials Data

Kazia Therapeutics Limited ADR (KZIA) Net Income 2024

KZIA net income (TTM) was -$13.52 million for the quarter ending June 30, 2023.

Kazia Therapeutics Limited ADR (KZIA) Cash Flow 2024

KZIA recorded a free cash flow (TTM) of -$10.03 million for the quarter ending June 30, 2023.

Kazia Therapeutics Limited ADR (KZIA) Earnings per Share 2024

KZIA earnings per share (TTM) was -$0.74 for the quarter ending June 30, 2023.

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.